


# Cancer Electrical Nutrition *(references)*



## Hope for the Hopeless 2012 Conference

**Presenter: Steve Haltiwanger MD, CCN**

### Presentation References:

1. Adámek J, Prausová J, Wald M. [Enzyme therapy in the treatment of lymphedema in the arm after breast carcinoma surgery]. *Rozhl Chir.* 1997 Apr;76(4):203-4.
2. Adey WR. Tissue interactions with nonionizing electromagnetic fields. *Physiol Rev* 1981; 61:435-514.
3. Adey WR. Physiological signaling across cell membranes and cooperative influences of extremely low frequency electromagnetic fields. In: *Biological Coherence and Response to External Stimuli*, H. Frohlich, ed., Heidelberg, Springer-Verlag, pgs 148-170, 1988.
4. Adey WR. Whispering Between Cells: Electromagnetic fields and regulatory mechanism in tissue. *Frontier Perspectives* 1993a;3(2):21-25.
5. Adey WR. Electromagnetics in biology and medicine. In *Modern Radio Science*, (ed. H. Matsumoto). Oxford, England: Oxford University Press, pgs 277-245, 1993.
6. Anfossi G, Russo I, Massucco P, Mattiello L, Cavalot F, Trovati M. N-acetyl-L-cysteine exerts direct anti-aggregating effect on human platelets. *Eur J Clin Invest.* 2001 May;31(5):452-61.
7. Aggarwal BB, Shishodia S. Molecular targets of dietary agents for prevention and therapy of cancer. *Biochem Pharmacol.* 2006 May 14;71(10):1397-421.
8. Allman MA, Pena MM, Pang D. Supplementation with flaxseed oil versus sunflowerseed oil in healthy young men consuming a low fat diet: effects on platelet composition and function. *Eur J Clin Nutr.* 1995 Mar;49(3):169-78.
9. Al-Mehdi AB, Tozawa K, Fisher AB, et al. Intravascular origin of metastasis from the proliferation of endothelium-attached tumor cells: a new model for metastasis. *Nat Med.* 2000 Jan;6(1):100-2.
10. Alpern RJ, Sakhaee K. The clinical spectrum of chronic metabolic acidosis: homeostatic mechanisms produce significant morbidity. *Am J Kidney Dis.* 1997;29:291–302.
11. Araújo JR, Gonçalves P, Martel F. Modulation of glucose uptake in a human choriocarcinoma cell line (BeWo) by dietary bioactive compounds and drugs of abuse. *J Biochem.* 2008 Aug;144(2):177-86.
12. Arnett T. Regulation of bone cell function by acid-base balance. *Proc Nutr Soc.* 2002;62:511–520.
13. Barger JF, Plas DR. Balancing biosynthesis and bioenergetics: metabolic programs in oncogenesis. *Endocr Relat Cancer.* 2010 Sep 23;17(4):R287-304.
14. Baxevanis CN, Reclus GJ, Gritzapis AD, et al. Elevated prostaglandin E2 production by monocytes is responsible for the depressed levels of natural killer and lymphokine-activated killer cell function in patients with breast cancer. *Cancer.* 1993; 72:491-501.
15. Beal J. Biosystem Liquid Crystals: Several hypotheses relating to interacting mechanisms which may explain biosystem and human hypersensitivities to electric and magnetic fields. 1996a. Website:<http://www.cyberspaceorbit.com/BIOSYSTEMLIQUIDCRYSTALS> by JamesBeal.htm.
16. Beal JB. Biosystems liquid crystals & potential effects of natural & artificial electromagnetic fields (EMFs) 1996b. Website: <http://frontpage.simnet.is/vgv/jim1.htm>
17. Beard J. *The enzyme treatment of cancer and its scientific basis: being collected papers dealing with the origin, nature, and scientific treatment of the natural phenomenon known as malignant disease.* NY: New Spring Press, 2009.
18. Belt JA, Thomas JA, Buchsbaum RN, Racker E. Inhibition of lactate transport and glycolysis in Ehrlich ascites tumor cells by bioflavonoids. *Biochemistry.* 1979 Aug 7;18(16):3506-11.

19. Beretz A, Cazenave JP. Old and new natural products as the source of modern antithrombotic drugs. *Planta Med.* 1991 Oct;57(7 Suppl):S68-72.
20. Beuth J. Proteolytic enzyme therapy in evidence-based complementary oncology: fact or fiction? *Integr Cancer Ther.* 2008 Dec;7(4):311-6.
21. Beuth J, Ost B, Pakdaman A, et al. Impact of complementary oral enzyme application on the postoperative treatment of breast cancer patients: results of an epidemiological multicentre retrospective cohort study. *Cancer Chemother Pharmacol.* 2001;47:45-54.
22. Biggerstaff JP, Weidow B, Dexheimer J, et al. Soluble fibrin inhibits lymphocyte adherence and cytotoxicity against tumor cells: implications for cancer metastasis and immunotherapy. *Clin Appl Thromb Hemost.* 2008 Apr;14(2):193-202.
23. Bobek V, Kovarik J. Antitumor and antimetastatic effect of warfarin and heparins. *Biomed Pharmacother.* 2004 May;58(4):213-9.
24. Boik J. *Natural Compounds in Cancer Therapy.* Oregon Medical Press, 2001.
25. Borregaar N, Herlin T. Energy metabolism of human neutrophils during phagocytosis. *J Clin Invest.* 1982;70:550–557.
26. Brouwer MA, Clappers N, Verheugt FWA. Adjunctive treatment in patients treated with thrombolytic therapy. *Heart* 2004;90:581-588.
27. Brown G. *The Energy of Life: The Science of What Makes Our Minds and Bodies Work.* New York, NY: The Free Press, 1999.
28. Bull RJ. Thresholds in Toxic Responses to Chemicals and Radiation and Their Use in Risk Assessment and Regulation. National Rural Water Association. White paper, June 21, 2001.
29. Cairns RA, Khokha R, Hill RP. Molecular mechanisms of tumor invasion and metastasis: an integrated view. *Curr Mol Med.* 2003 Nov;3(7):659-71.
30. Calderon-Montano J , Burgos-Moron E , Perez-Guerrero C , Salvador J , Robles A , Lopez-Lazaro M . Role of the Intracellular pH in the Metabolic Switch between Oxidative Phosphorylation and Aerobic Glycolysis - Relevance to Cancer . *WebmedCentral CANCER* 2011;2(3):WMC001716
31. Cardone RA, Casavola V, Reshkin SJ. The role of disturbed pH dynamics and the Na<sup>+</sup>/H<sup>+</sup> exchanger in metastasis. *Nat Rev Cancer.* 2005 Oct;5(10):786-95.
32. Carere A. Genotoxicity and carcinogenicity of acrylamide: a critical review. *Ann Ist Super Sanita.* 2006;42(2):144-55.
33. Cone CD. Variation of the transmembrane potential level as a basic mechanism of mitosis control. *Oncology* 1970;24:438-470.
34. Cone CD, Jr . Unified theory on the basic mechanism of normal mitotic control and oncogenesis. *J Theor Biol.* 1971;30:151-181.
35. Cone CD. The role of surface electrical transmembrane potential in normal and malignant mitogenesis. *Ann NY Acad Sci* 1975;238:420-35.
36. Cone CD. *Transmembrane Potentials and Characteristics of Immune and Tumor Cells.* Boca Raton, Florida: CRC Press, 1985.
37. Cope FW. A medical application of the Ling Association-Induction Hypothesis: The high potassium, low sodium diet of the Gerson cancer therapy. *Physiol Chem Phys* 1978;10(5):465-468.
38. Corsi MP, De Martinis M, Di Leonardo G, et al. Blood coagulation changes and neoplastic pathology. *Recenti Prog Med.* 2000 Oct;91(10):532-7.
39. Cure JC. On the electrical characteristics of cancer. Paper presented at the Second International Congress of Electrochemical Treatment of Cancer. Jupiter, Florida: October 1995.
40. Dale PS, Tamhankar CP, George D, Daftary GV. Comedication with hydrolytic enzymes in radiation therapy of uterine cervix: evidence of the reduction of acute side effects. *Cancer Chemother Pharmacol.* 2001;47(Suppl):S29-S34.
41. Dallos P. Neurobiology of cochlear inner and outer hair cells: intracellular recordings. *Hear Res* 1986;22:185-198.

42. Davey CL, Kell DB. The dielectric properties of cells and tissues: What can they tell us about the mechanisms of field/cell interactions? In: O'Connor ME, Bentall RHC, Monahan JC, eds. *Emerging Electromagnetic Medicine*. New York, NY:Springer-Verlag, 1990:19-43.
43. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. (2008) The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. *Cell Metab*. 2008;7:11–20.
44. Demetrakopoulos GE, Brennan MF. Tumorcidal potential of nutritional manipulations. *Cancer Res (Suppl)* 1982; 42:756s-65s.
45. De Milito A, Fais S. Tumor acidity, chemoresistance and proton pump inhibitors. *Future Oncol*. 2005 Dec;1(6):779-86.
46. Dempke W, Rie C, Grothey A, Schmoll HD. Cyclooxygenase-2:a novel target for cancer chemotherapy? *J Cancer Res Clin Oncol*. 2001;127:411-417.
47. Desser L, Sakalova A, Zavadova E, Holomanova D, Mohr T. Oral enzyme therapy improves remission time, soluble TNF-receptors and  $\alpha_2$ -microglobulin concentration in chemotherapy treated multiple myeloma patients. *Int J Tissue React*. 1997;19: 94.
48. Desser L, Holomanova D, Zavadova E, Pavelka K, Mohr T, Herbacek I. Oral therapy with proteolytic enzymes decreases excessive TGF- $\beta$  levels in human blood. *Cancer Chemother Pharmacol*. 2001;47(suppl):S10-S15.
49. Donaldson MS. Nutrition and cancer: a review of the evidence for an anti-cancer diet. *Nutr J*. 2004 Oct 20;3:19.
50. Dutta-Roy AK, Crosbie L, Gordon MJ. Effects of tomato extract on human platelet aggregation in vitro. *Platelets*. 2001 Jun;12(4):218-27.
51. Egyud LG, Lipinski B. Significance of fibrin formation and dissolution in the pathogenesis and treatment of cancer. *Med Hypotheses*. 1991 Dec;36(4):336-40.
52. Erler JT, Bennewith KL, Nicolau M, et al. Lysyl oxidase is essential for hypoxia-induced metastasis. *Nature*. 2006 Apr 27;440(7088):1222-6.
53. Falanga A, Marchetti M, Vignoli A, Balducci D. Clotting mechanisms and cancer: implications in thrombus formation and tumor progression. *Clin Adv Hematol Oncol*. 2003 Nov;1(11):673-8.
54. Franchini M, Montagnana M, Favaloro EJ, Lippi G. The bidirectional relationship of cancer and hemostasis and the potential role of anticoagulant therapy in moderating thrombosis and cancer spread. *Semin Thromb Hemost*. 2009 Oct;35(7):644-53.
55. Francis JL, Amirkhosravi A. Effect of antihemostatic agents on experimental tumor dissemination. *Semin Thromb Hemost*. 2002 Feb;28(1):29-38.
56. Fuster MM, Esko JD. The sweet and sour of cancer: glycans as novel therapeutic targets. *Nat Rev Cancer*. 2005 Jul;5(7):526-42.
57. Gabig TG, Bearman SI, Babior BM. Effects of oxygen tension and pH on the respiratory burst of human neutrophils. *Blood*. 1979; 53: 1133–1139.
58. Ganapathy V, Thangaraju M, Prasad PD. Nutrient transporters in cancer: relevance to Warburg hypothesis and beyond. *Pharmacol Ther*. 2009 Jan;121(1):29-40.
59. Garnett M. *First Pulse: A Personal Journey in Cancer Research*. New York, NY: First Pulse Projects, 1998.
60. Garnett M, Remo JL, Krishnan CV. Developmental electronic pathways and carcinogenesis. Garnett McKeen Laboratory, Inc. 150 Islip Ave. Suite 6, Islip, New York 11751. [http://www.polymva-survivors.com/research\\_articles.html](http://www.polymva-survivors.com/research_articles.html), 2002
61. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? *Nat Rev Cancer*. 2004 Nov;4(11):891-9.
62. Glaves D. Role of polymorphonuclear leukocytes in the pulmonary clearance of arrested cancer cells. *Invasion Metastasis*. 1983;3:160–73.
63. Gonzalez NJ. *One Man Alone: An Investigation of Nutrition, Cancer, and William Donald Kelley*. NY: New Spring Press, 2010.

64. Gonzalez NJ, Isaacs LL. *The Trophoblast and the Origins of Cancer: One solution to the medical enigma of our time*. NY: New Spring Press, 2009.
65. Gonzalez NJ. *Enzymes and Cancer* - DVD (Dec. 29, 2008). [www.amazon.com](http://www.amazon.com)
66. Gonzalez NJ, Isaacs LL. *The Gonzalez therapy and cancer: a collection of case reports*. *Altern Ther Health Med*. 2007 Jan-Feb;13(1):46-55.
67. Gonzalez NJ. "The Enzyme Therapy of Cancer" Seminar. 7-disc CDs (7 hours). NY: New Spring Press, 2009. <http://www.newspringpress.com/catalog.html>
68. Gonzalez NJ. *Holistic Cancer Therapy Part 1, 2 & 3*. DVD version (6 hours) [http://www.fleetwoodonsite.com/product\\_info.php?cPath=40\\_274&products\\_id=9343](http://www.fleetwoodonsite.com/product_info.php?cPath=40_274&products_id=9343)
69. Gunji Y, Lewis J, Gorelik E. Fibrin formation inhibits the in vitro cytotoxic activity of human natural and lymphokine-activated killer cells. *Blood Coagul Fibrinolysis*. 1990;1:663-672.
70. Hanna N, Fidler IJ. Role of natural killer cells in the destruction of circulating tumor emboli. *J Natl Cancer Inst*. 1980;65:801-9.
71. Hara Y, Steiner M, Baldini MG. Platelets as a source of growth-promoting factor(s) for tumor cells. *Cancer Res*. 1980;40:1212-6.
72. Hejna M, Raderer M, Zielinski CC. Inhibition of metastases by anticoagulants. *J Natl Cancer Inst*. 1999 Jan 6;91(1):22-36.
73. Ho MW. *The Rainbow and the Worm: The Physics of Organisms*, 2nd ed. River Edge, NJ: World Scientific, 1998.
74. Hsu PP, Sabatini DM. Cancer cell metabolism: Warburg and beyond. *Cell*. 2008 Sep 5;134(5):703-7.
75. Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. *Nat Rev Cancer*. 2009 Apr;9(4):239-52.
76. Kang WS, Lim IH, Yuk DY, Chung KH, Park JB, Yoo HS, Yun YP. Antithrombotic activities of green tea catechins and (-)-epigallocatechin gallate. *Thromb Res*. 1999 Nov 1;96(3):229-37.
77. Kato Y, Nakayama Y, Umeda M, Miyazaki K. Induction of 103-kDa gelatinase/ type IV collagenase by acidic culture conditions in mouse metastatic melanoma cell lines. *J Biol Chem*. 1992;267: 11424-11430.
78. Kellum JA, Song M, Li J. Science review: extracellular acidosis and the immune response: clinical and physiologic implications. *Crit Care*. 2004 Oct;8(5):331-6.
79. Kerbel RS. Tumor angiogenesis: Past, present and the near future. *Carcinogenesis*. 2000 Mar; 21(3):505-15.
80. Key ME. Macrophages in cancer metastases and their relevance to metastatic growth. *Cancer Metastasis Rev*. 1983;2:75-88.
81. Korte W. Changes of the coagulation and fibrinolysis system in malignancy: their possible impact on future diagnostic and therapeutic procedures. *Clin Chem Lab Med*. 2000 Aug;38(8):679-92.
82. Kraus M, Wolf B. Physicochemical microenvironment as key regulator for tumor microevolution, invasion and immune response: targets for endocytotechnological approaches in cancer treatment. *Endocytobiol Cell Res*. 1998; 12:133-156.
83. Kueck A, Opiari AW Jr, Griffith KA, et al. Resveratrol inhibits glucose metabolism in human ovarian cancer cells. *Gynecol Oncol*. 2007 Dec;107(3):450-7.
84. Lah TT, Kos J. Cysteine proteinases in cancer progression and their clinical relevance for prognosis. *Biol Chem*. 1998;379:125-130.
85. Lardner A: The effects of extracellular pH on immune function. *J Leukoc Biol*. 2001;69:522-530.
86. Leipner J, Saller R. Systemic enzyme therapy in oncology: effect and mode of action. *Drugs*. 2000 Apr;59(4):769-80.
87. Lipinski B, Egyud LG. Resistance of cancer cells to immune recognition and killing. *Med Hypotheses*. 2000 Mar;54(3):456-60.
88. Liu J. THE APPLICATION OF METABOLIC NETWORK ANALYSIS IN UNDERSTANDING AND TARGETING METABOLISM FOR DRUG DISCOVERY. Dissertation. Dec 3, 2010. <http://etd.library.pitt.edu/ETD/available/etd-12072010-100902/>

89. Loeffler DA, Juneau PL, Heppner GH. Natural killer-cell activity under conditions reflective of tumor micro-environment. *Int J Cancer*. 1991;48:895-899.
90. Lopez-Lazaro M. The Warburg effect: why and how do cancer cells activate glycolysis in the presence of oxygen? *Anticancer Agents Med. Chem.* 2008;8:305-312.
91. Lu H, Ouyang W, Huang C. Inflammation, a key event in cancer development. *Mol Cancer Res*. 2006 Apr;4(4):221-33.
92. Lyman GH, Khorana AA. Cancer, clots and consensus: new understanding of an old problem. *J Clin Oncol*. 2009 Oct 10;27(29):4821-6.
93. Marquardt H. Chemical Carcinogenesis Chapter 7. In: Marquardt, H., Schafer, S.G., McClellan, R.D. and Welsch, F. (Eds.) *Toxicology*. NY: Academic Press, pp. 151-179, 1999.
94. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. *Nature*. 2008;454:436-444.
95. Mathupala SP, Rempel A, Pedersen PL. Aberrant glycolytic metabolism of cancer cells: a remarkable coordination of genetic, transcriptional, post-translational, and mutational events that lead to a critical role for type II hexokinase. *J Bioenerg Biomembr*. 1997 Aug;29(4):339-43.
96. McEwen B, Morel-Kopp MC, Tofler G, Ward C. Effect of omega-3 fish oil on cardiovascular risk in diabetes. *Diabetes Educ*. 2010 Jul-Aug;36(4):565-84.
97. Medhekar R: The first quantitative evidence proving the efficacy of supplemental enzymes. In Forsyth, MO: National Enzyme Company, Inc 2004.
98. Mousa SA. Anticoagulants in thrombosis and cancer: the missing link. *Semin Thromb Hemost*. 2002 Feb;28(1):45-52.
99. Mousa SA. Anti-thrombotics in thrombosis and cancer. *Future Oncol*. 2005 Jun;1(3):395-403.
100. Mousa SA Role of current and emerging antithrombotics in thrombosis and cancer. *Timely Top Med Cardiovasc Dis*. 2006 Aug 1;10:E19.
101. Mousa SA, Petersen LJ. Anti-cancer properties of low-molecular-weight heparin: preclinical evidence. *Thromb Haemost*. 2009 Aug;102(2):258-67.
102. Nagy IZ, Lustyik G, Nagy VZ, Zarándi B, Bertoni-Freddari C. Intracellular Na<sup>+</sup>:K<sup>+</sup> ratios in human cancer cells as revealed by energy dispersive x-ray microanalysis. *J Cell Biol*. 1981 Sep;90(3):769-77.
103. Nieswandt B, Hafner M, Echtenacher B, Mannel DN. Lysis of tumor cells by natural killer cells in mice is impeded by platelets. *Cancer Res*. 1999;59:1295-1300.
104. Novak JF, Trnka F. Proenzyme therapy of cancer. *Anticancer Res*. 2005 Mar-Apr;25(2A):1157-77.
105. O'Kennedy N, Crosbie L, van Lieshout M, Broom JI, Webb DJ, Duttaroy AK. Effects of antiplatelet components of tomato extract on platelet function in vitro and ex vivo: a time-course cannulation study in healthy humans. *Am J Clin Nutr*. 2006 Sep;84(3):570-9.
106. Olszewski-Hamilton U, Hamilton G. Dependence of Relative Expression of NTR1 and EGFR on Cell Density and Extracellular pH in Human Pancreatic Cancer Cell Lines. *Cancers*. 2011;3:182-197.
107. O'Meara RA. Coagulative properties of cancer. *Irish J Med Sci*. 1958;6:474-9.
108. Palumbo JS. Mechanisms linking tumor cell-associated procoagulant function to tumor dissemination. *Semin Thromb Hemost*. 2008;34:154-160.
109. Pan MH, Lai CS, Dushenkov S, Ho CT. Modulation of inflammatory genes by natural dietary bioactive compounds. *J Agric Food Chem*. 2009 Jun 10;57(11):4467-77.
110. Pardoll D. T cells take aim at cancer. *PNAS*. 2002 Dec 10;99(25):15840-15842.
111. Peinado H, Cano A. A hypoxic twist in metastasis. *Nat Cell Biol*. 2008 Mar;10(3):253-4.
112. Popiela T, Kulig J, Hanisch J, Bock PR. Influence of complementary treatment with oral enzymes on patients with colorectal cancers: an epidemiological retrospective cohort study. *Cancer Chemother Pharmacol*. 2001;47:55-63.
113. Porta C, Larghi P, Rimoldi M, et al. Cellular and molecular pathways linking inflammation and cancer. *Immunobiology*. 2009;214(9-10):761-77.
114. Prasad K. Flaxseed and cardiovascular health. *J Cardiovasc Pharmacol*. 2009 Nov;54(5):369-77.

115. Prasad S, Phromnoi K, Yadav VR, Chaturvedi MM, Aggarwal BB. Targeting inflammatory pathways by flavonoids for prevention and treatment of cancer. *Planta Med.* 2010 Aug;76(11):1044-63.
116. Rath M. [http://www4.dr-rath-foundation.org/pdf-files/cancer\\_book.pdf](http://www4.dr-rath-foundation.org/pdf-files/cancer_book.pdf) MR Publishing, Inc., Santa Clara CA, 2001.
117. Read MA. Flavonoids: Naturally occurring anti-inflammatory agents [comment]. *Am J Pathol* 1995 Aug; 147(2):235–7.
118. Reichart LF. Extracellular matrix molecules. In *Guidebook to the Extracellular Matrix, Anchor, and Adhesion Proteins*, (ed. T. Kreis and R. Vale). Oxford, England: Oxford University Press, pgs. 335-344, 1999.
119. Reilly JP. *Applied Bioelectricity: From Electrical Stimulation to Electropathology*. New York: Springer, 1998.
120. Remer T. Influence of nutrition on acid-base balance – metabolic aspects. *Eur J Nutr.* 2001;40:214-220.
121. Remer T, Manz F. Potential renal acid load of foods and its influence on urine pH. *J Am Diet Assoc.* 1995; 95(7): 791-7.
122. Reshkin SJ, Bellizzi A, Caldeira S, et al. Na<sup>+</sup>/H<sup>+</sup> exchanger-dependent intracellular alkalinization is an early event in malignant transformation and plays an essential role in the development of subsequent transformation-associated phenotypes. *FASEB J.* 2000;14:2185-2197.
123. Revici E. *Research in Pathophysiology as Basis for Guided Chemotherapy, with Special Application to Cancer*. Princeton, NJ: D. Van Nostrand Company, 1961.
124. Rivenzon-Segal D, Boldin-Adamsky S, Seger D, et al. Glycolysis and glucose transporter 1 as markers of response to hormonal therapy in breast cancer. *Int J Cancer.* 2003;107:177–182.
125. Robey IF, Baggett BK, Kirkpatrick ND, Roe DJ, et al. Bicarbonate increases tumor pH and inhibits spontaneous metastases. *Cancer Res.* 2009 Mar 15;69(6):2260-8.
126. Rotin D, Steele-Norwood D, Grinstein S, Tannock I. Requirement of the Na<sup>+</sup>/H<sup>+</sup> exchanger for tumor growth. *Cancer Res.* 1989;49: 205-211.
127. Russell IJ, Cody AR, Richardson GP. The response of inner and outer hair cells in the basal turn of the guinea pig cochlea and in the mouse cochlea grown in vitro. *Hear Res* 1986;22:199-216.
128. Rylander R, Remer T, Berkemeyer S, et al. Acid-base status affects renal magnesium losses in healthy, elderly persons. *Journal of Nutrition.* 2006;136:2374-2377.
129. Sauvant C, Nowak M, Wirth C, et al. Acidosis induces multi-drug resistance in rat prostate cancer cells (AT1) in vitro and in vivo by increasing the activity of the p-glycoprotein via activation of p38. *Int J Cancer.* 2008 Dec 1;123(11):2532-42.
130. Seeger PG, Wolz S. *Successful Biological Control of Cancer: By Combat Against the Causes*. Gesamtherstellung: Neuwieder Verlagsgesellschaft mbH, 1990.
131. Semenza GL, Artemov D, Bedi A, et al. 'The metabolism of tumours': 70 years later. *Novartis Found Symp.* 2001;240:251-60; discussion 260-4.
132. Semenza GL. Targeting HIF-1 for cancer therapy. *Nat Rev Cancer.* 2003;3:721-732.
133. Semenza GL. Tumor metabolism: cancer cells give and take lactate. *J Clin Invest.* 2008 Dec;118(12):3835-7.
134. Seyfried TN, Shelton LM. Cancer as a metabolic disease. *Nutr Metab (Lond).* 2010 Jan 27;7:7.
135. Shah BH, Nawaz Z, Pertani SA, Roomi A, Mahmood H, Saeed SA, Gilani AH. Inhibitory effect of curcumin, a food spice from turmeric, on platelet-activating factor- and arachidonic acid-mediated platelet aggregation through inhibition of thromboxane formation and Ca<sup>2+</sup> signaling. *Biochem Pharmacol.* 1999 Oct 1;58(7):1167-72.
136. Shim CK, Cheon EP, Kang KW, Seo KS, Han HK. Inhibition effect of flavonoids on monocarboxylate transporter 1 (MCT1) in Caco-2 cells. *J Pharm Pharmacol.* 2007 Nov;59(11):1515-9.
137. Sica A. Role of tumour-associated macrophages in cancer-related inflammation. *Exp Oncol.* 2010 Sep;32(3):153-8.

138. Siemann DW. Vascular targeting agents. *Horizons in Cancer Therapeutics: From Bench to Bedside*. 2002;3(2):4-15.
139. Sierko E, Wojtukiewicz MZ. Inhibition of platelet function: does it offer a chance of better cancer progression control? *Semin Thromb Hemost*. 2007 Oct;33(7):712-21.
140. Silva AS, Yunes JA, Gillies RJ, Gatenby RA. The potential role of systemic buffers in reducing intratumoral extracellular pH and acid-mediated invasion. *Cancer Res*. 2009 Mar 15;69(6):2677-84.
141. Sion AM, Figg WD. Lysyl oxidase (LOX) and hypoxia-induced metastases. *Cancer Biol Ther*. 2006 Aug;5(8):909-11.
142. Stock C, Mueller M, Kraehling H, et al. pH Nanoenvironment at the Surface of Single Melanoma Cells. *Cell Physiol. Biochem*. 2007;20:679-686.
143. Stubbs M, Veech RL, Griffiths JR. Tumor metabolism: the lessons of magnetic resonance spectroscopy. *Advances in Enzyme Regulation*. 1995;35:101-115.
144. Taylor CT, Colgan SP. Hypoxia and gastrointestinal disease. *J Mol Med*. 2008;85:1295–1300.
145. Tenforde TS, Kaune WT. Interaction of extremely low frequency electric and magnetic fields with humans. *Health Phys*. 1987;53:585-606.
146. Thornes RD. Adjuvant therapy of cancer via the cellular immune mechanism or fibrin by induced fibrinolysis and oral anticoagulants. *Cancer*. 1975 Jan;35(1):91-7.
147. Trivedi B, Danforth WH. Effect of pH on the kinetics of frog muscle phosphofructokinase. *J Biol Chem*. 1966;241:4110-4112.
148. Tsai CS. *An Introduction to Computational Biochemistry*. Wiley-Liss, Inc, pp. 123-146, 2002.
149. Tsong TY. Deciphering the language of cells. *Trends in Biochemical Sciences* 1989;14:89-92
150. Tucker KL, Hannan MT, Chen H, Cupples LA, Wilson PW, Kiel DP. Potassium, magnesium, and fruit and vegetable intakes are associated with greater bone mineral density in elderly men and women. *Am J Clin Nutr*. 1999;69:727–36.
151. van Kempen LC, de Visser KE, Coussens LM. Inflammation, proteases and cancer. *Eur J Cancer*. 2006 Apr;42(6):728-34.
152. Van QN, Veenstra TD. How close is the bench to the bedside? Metabolic profiling in cancer research. *Genome Med*. 2009 Jan 20;1(1):5.
153. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. *Science*. 2009 May 22;324(5930):1029-33.
154. Vermeulen ME, Gamberale R, Trevani AS, et al. The impact of extracellular acidosis on dendritic cell function. *Crit Rev Immunol*. 2004;24(5):363-84.
155. Volk C, Kempfski B, Kempfski OS. Inhibition of lactate export by quercetin acidifies rat glial cells in vitro. *Neurosci Lett*. 1997 Feb 21;223(2):121-4.
156. Wallace JM. Nutritional and botanical modulation of the inflammatory cascade--eicosanoids, cyclooxygenases, and lipoxygenases--as an adjunct in cancer therapy. *Integr Cancer Ther*. 2002 Mar;1(1):7-37.
157. Warburg O. On the origin of cancer cells. *Science* 1956 Feb;123:309-14.
158. Wang Q, Morris ME. Flavonoids modulate monocarboxylate transporter-1-mediated transport of gamma-hydroxybutyrate in vitro and in vivo. *Drug Metab Dispos*. 2007 Feb;35(2):201-8.
159. Ward PS. History of the Gerson therapy. Contract report prepared for the U.S. Office of Technology Assessment. U.S. Government Printing Office, 1988 <http://gerson-research.org/docs/WardPS-1988-1/index.html>
160. Welch AA. Dipstick Measurements of Urinary pH have Potential for Monitoring Individual and Population Dietary Behaviors. *Open Nutrition Journal*. 2008;2:63-67.
161. Wollschlaeger B. Integrative Treatment Modalities in Cancer Care: The Good, the Bad, and the Ugly. *JANA*. 2007;10(2):3-4.
162. Zhang X, Lin Y, Gillies RJ. Tumor pH and its measurement. *J Nucl Med*. 2010 Aug;51(8):1167-70